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Abstract 007 – Table 1. Raw KOOS scores (non-normalized) were used for purposes of statistical analysis
KOOS Subscale Anakinra Treatment Placebo Treatment
Result Mean (SD) Mean (SD) Mean Change (SD) P value Result Mean (SD) Mean (SD) Mean Change (SD) P value
1st timepoint 2nd timepoint 1st timepoint 2nd timepoint
Pain 0> 4 16.7 (7.26) 12.8 (4.4) –3.8 (3.4) 0.043 0 = 4 15.4 (5.4) 12.6 (2.07) –0.6 (2.6) NS
ADL 0> 4 23.0 (14.4) 12.5 (7.1) –10.5 (7.7) 0.028 0 = 4 21.8 (7.3) 20.4 (3.0) –1.4 (8.6) NS
Total 0> 4 85.0 (31.2) 64.7 (25.8) –20.3 (6.7) 0.028 0 = 4 81.2 (16.5) 75.8 (6.2) –5.4 (16.5) NS
QOL 0 > 4 12.8 (4.3) 11.7 (3.9) –1.2 (1.3) 0.084 0 = 4 13.4 (1.8) 12.6 (2.2) –0.8 (1.9) NS
Other Symptoms 0 > 4 13.5 (5.9) 12.0 (7.1) –1.5 (2.1) 0.102 0 > 4 15.4 (5.4) 12.6 (5.3) –2.8 (2.6) 0.080
Sports Function 0 > 4 19 (1.3) 15.7 (4.9) –3.3 (3.7) 0.102 0 = 14 17.4 (3.7) 17.6 (2.4) 0.2 (3.6) NS
ADL 4 > 14 12.5 (7.1) 7.5 (6.2) –5 (4.24) 0.066 4 = 14 20.4 (3.0) 21.4 (7.2) 1 (7.9) NS
Total 4 > 14 64.7 (25.8) 48.3 (28.2) –15 (11.5) 0.066 4 = 14 75.8 (6.2) 77.4 (14.4) 1.6 (13.7) NS
Pain 4 > 14 12.8 (4.4) 9.5 (6.0) –3.0 (2.9) 0.109 4 = 14 12.6 (2.1) 12.8 (4.0) 0.2 (4.8) NS
QOL 4 > 14 11.7 (3.9) 10.3 (4.9) –1.25 (1.0) 0.102 4 < 14 12.6 (2.2) 13.2 (1.92) 0.6 (0.5) 0.083
Sports Function 4 > 14 15.7 (4.9) 12.8 (6.9) –5.0 (4.2) 0.102 4 = 14 17.6 (2.4) 17.4 (3.2) –0.2 (3.0) NS
For purposes of interpretation, 0 > 4 means score at Day 0 was greater than at Day 4, decline in severity over time.
Pain = KOOS pain; ADL = KOOS activities of daily living; QOL = KOOS quality of life subscale; Total = combination of 5 subscales: Pain, ADL and QOL and Other Symptoms and Function in
Sports and Recreation. P value by Wilcoxon rank sum test.
immunoassay (Corgenix; intra- and inter-assay CVs were 2% and 3%
respectively).
Functional Outcomes: The standardized KOOS questionnaire was obtained at
baseline (0), 4 days, 14 days, and 28 days or the day of surgery.
Statistical Analysis: The Wilcoxon rank sum test was used to evaluate the
change in KOOS from baseline to follow-up within a treatment group.
Two-tailed t-test was used to compare the change scores (pre-post synovial
ﬂuid concentrations) between placebo and drug treated groups.
Results: As shown in the table, the Anakinra group had substantially
greater improvement (∼1-3 s.d.) in key outcomes whereas the placebo
group had much less improvement (∼1/4 of s.d. on most outcomes).
Statistically signiﬁcant improvements in KOOS pain (p=0.04) and function
(activities of daily living, p=0.03), and total KOOS (p=0.03) were observed
in response to IL1-Ra, but not placebo. In the anakinra treated group this
corresponded to reductions in Pain of 23%, improvement in Activities of
Daily Living of 46%, and improvement in total KOOS of 24%; in contrast, the
placebo group changed only 4%, 6% and 7% for these outcomes respectively.
There were no adverse reactions in either the anakinra or saline placebo
treated groups.
Synovial ﬂuid IL-1α, IL-1β, and IL-1Ra concentrations exceeded serum
concentrations. IL-1α increased in all the placebo treated patients whereas
it decreased in 4 of 5 of the anakinra treated patients (p=0.05). Although
IL-1 and IL-1Ra declined dramatically over time post injury, there was no
signiﬁcant difference based on treatment. Serum HA decreased in all the
anakinra treated patients (n=6 pairs) from Time 1 to Time 2 (p=0.03) while
the change in the placebo treated patients was not signiﬁcant.
Conclusions: IL-1Ra decreased pain and improved function in our random-
ized pilot trial of acute knee injury. The decreases in serum HA and synovial
ﬂuid IL-1α in the IL-1Ra treated patients are consistent with a decrease in
synovial inﬂammation in acute knee injury in response to IL-1Ra therapy.
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Purpose: Magnetic resonance imaging (MRI)-detected subchondral bone
marrow lesions (BML) are frequently seen in osteoarthritis (OA) of the knee
depicting acute and chronic changes in this tissue. They have been shown
to predict cartilage loss and to correlate with pain. However, the literature
remains contradictory about the latter. Furthermore, we lack knowledge
about treatment effects on BML. The aim of this study was to assess, in a
multicentre randomized double-blind phase III clinical trial evaluating the
effect of licofelone vis-à-vis naproxen on knee OA, the presence of and
change in BML over time and their relationship to cartilage volume loss,
meniscal extrusion, and pain.
Methods: Knee OA patients were selected from the dataset of a recently
published randomized controlled trial [1]. One hundred and sixty-one
patients completed the study according to protocol. MRI was performed
at baseline, 6, 12, and 24 months to assess BML score and cartilage
volume changes over time. Pain levels were assessed using the WOMAC
questionnaire.
Results: Both treatment groups showed increased BML scores compared to
baseline in the global knee (both treatments combined: 0.71±1.85 [mean
±SD], p<0.0001, 24 months) and in all subregions except for the medial tib-
ial plateau where the BML score in the licofelone group remained stable at
12 (-0.01±0.37) and 24 months (-0.01±0.65) vis-à-vis an ongoing increase
in the naproxen group (0.15±0.58, p=0.04; 0.21±0.74, p=0.06, respectively).
In multivariate regression analysis, licofelone treatment predicted reduc-
tion in BML score in the medial tibial plateau (β estimate=-0.27, p=0.02) and
severe meniscal extrusion predicted progression (β estimate=0.26, p=0.03).
BML scores at baseline statistically correlated with cartilage volume (me-
dial, r=-0.24, p=0.002; lateral, r=-0.28, p=0.0003; femoropatellar, r=-0.28,
p=0.0003). In the global and medial compartments, BML score increases
correlated with cartilage loss at 12 months (r=-0.18, p=0.03; r=-0.19, p=0.02,
respectively). No correlation was found between BML and WOMAC pain
scores with the exception of an inverse correlation in the femoropatellar
compartment at 6 (r=-0.22, p=0.006) and 12 months (r=-0.24, p=0.002).
Conclusions: BML scores were found to increase over time, likely reﬂect-
ing an accumulation of chronic changes in subchondral bone tissue. The
correlation between BML and cartilage volume at baseline underlines a
close relationship between them. The reduction in BML might be due to
the unique action of licofelone not only on cyclooxygenases but also on
lipoxygenase. In contrast to previous reports, no positive relationship was
found between BML score (baseline or changes over time) and pain.
Reference
[1] Raynauld JP et al. Ann Rheum Dis 2009;68:938-47.
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Purpose: Bone marrow edema-like lesions (BMLs), which histologically
represent bone damage, are predictors of cartilage loss and pain in knee
osteoarthritis (OA) and represent potential treatment targets. Loss of carti-
lage as part of OA may actually remove a tissue protecting underlying bone,
increasing loading and possibly damage to bone, leading to BMLs. The aim
of this study was to assess the association of prevalent cartilage damage
and cartilage loss over time with incident BMLs in the same subregion of
the knee.
Methods: The Multicenter Osteoarthritis (MOST) Study is a NIH-funded
observational study of individuals who have or are at risk for knee OA.
